The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with ...

Tirzepatide is the active ingredient in Zepbound, the FDA approved prescription medicine for Obstructive Sleep Apnea.

By aiding weight loss, Zepbound can improve symptoms of obstructive sleep apnea (OSA) in people with obesity — but CPAP ...

Between 30-50% of adults with hypertension have OSA, and this number increases to between 70-80% in adults with resistant hypertension. Additionally, untreated moderate-to-severe OSA increases the ...

Zepbound, a popular weight loss drug, has become the first FDA-approved prescription medication to treat obstructive sleep ...

Zepbound, a drug approved by the FDA, has been shown to reduce the severity of obstructive sleep apnea in obese adults, ...

“Today’s approval marks the first drug treatment option for certain patients with obstructive sleep apnea,” said Sally Seymour, M.D., director of the Division of Pulmonology, Allergy, and Critical ...

The Link Between Obesity and Obstructive Sleep Apnea Obstructive sleep apnea ... the drug’s effectiveness was measured by the apnea-hypopnea index (AHI), which tracks the frequency of breathing ...

The first medication for obstructive sleep apnea has been approved by ... and clinically meaningful reduction in events of apnea or hypopnea," and a large share of participants achieved remission ...

Lancet 365: 1046–1053 Obstructive sleep apnea-hypopnea is widely considered to be a cardiovascular risk factor, but there are few prospective data to confirm this link or to establish whether ...